Register for a live broadcast to learn more about TRODELVY (sacituzumab govitecan-hziy) with Dr. Hope S. Rugo

Select Topic:
Browse by Series:

Somatostatin Analogue Dosing Strategies

INSIGHTS FROM: ZOZO GREENHOLZ, RN; ANDREW E. HENDIFAR, MD; ERIC LIU, MD, FACS; MARIAH MAHOTZ, RN, BSN, OCN
Thursday, January 23, 2020


Transcript:

Eric Liu, MD, FACS: The dosing of octreotide and lanreotide really varies and is up to the physician. If we start with octreotide, because it’s the older version, it comes in essentially 4 versions. The first version is what we call rescue octreotide. It’s a subcutaneous injection. You give it multiple times a day, and it’s mostly for symptom control. But when it comes to giving the long-acting repeatable version, the LAR version, it comes in 3 doses: 10 mg, 20 mg, and 30 mg.

What’s recommended is actually to help with the symptoms and to use the rescue version first. You make sure they tolerate it well and start with 20 mg, because then you increase the dose or decrease the dose. Of course, if someone has other issues, like liver problems or kidney problems, you may want to start at an even lower dose. But most patients go to 30 mg, and that’s the most common standard dose for octreotide.

Lanreotide is slightly different. It has 2 indications. One indication is for tumor control as well as symptom control. Lanreotide comes in 3 doses as well: 60 mg, 90 mg, and 120 mg. The recommended dose by the FDA for tumor control is 120 mg every 4 weeks, and that’s usually where we start. Of course the dosing is really up to the discretion of the physician. But if there are issues—for example, the patient doesn’t tolerate the higher dose so much or is very, very small, those are things to consider—reducing the dose is certainly something to consider. But it all depends, and we really leave it up to the discretion of the physician.

Transcript Edited for Clarity

Talk about this article with nurses and others in the oncology community in the General Discussions Oncology Nursing News discussion group.
Slider Left
Slider Right
External Resources

MJH Associates
American Journal of Managed Care
Cure
MD Magazine
Pharmacy Times
Physicians' Education Resource
Specialty Pharmacy Times
TargetedOnc
OncNurse Resources

Newsroom
Continuing Education
Discussions
Web Exclusives


About Us
Advertise
Advisory Board
Careers
Contact Us
Privacy Policy
Terms & Conditions
Intellisphere, LLC
2 Clarke Drive
Suite 100
Cranbury, NJ 08512
P: 609-716-7777
F: 609-716-4747

Copyright OncNursing 2006-2019
Intellisphere, LLC. All Rights Reserved.